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1. Introduction 
Blood glucose homeostasis is controlled by the endocrine cells of the pancreas,  located in 
the islets of Langerhans. The islet cells monitor the concentration of glucose in the blood and 
secrete hormones with opposite effects. When after a meal the blood glucose concentration is 
increasing, the beta cells, which are the most numerous islet cells, secrete the hormone 
insulin to reduce blood glucose. Insulin stimulates the uptake of glucose by cells of the body 
and stimulates the conversion of glucose to glycogen in the liver. If the glucose level falls too 
far, islet alpha cells secrete the hormone glucagon, which stimulates the breakdown of 
glycogen to glucose in the liver and therefore increases blood glucose between meals. 
Optimal control of blood glucose levels depends on delicate changes in insulin production 
and secretion by the pancreatic beta cells and on their capacity for a large increase of 
secretion after meals, requiring large stores of insulin [1]. Very important is the need for the 
beta-cell mass to be closely regulated by glucose and hormonal effects on beta-cell 
replication, size, apoptotic elimination and, under certain conditions, neogenesis from 
progenitor cells. Failure to adapt to changes in body mass, pregnancy, insulin sensitivity of 
peripheral tissues, or tissue injury may lead to the development of chronically elevated 
blood glucose, or diabetes [2]. The increasing global prevalence of diabetes  has stimulated 
efforts to develop new therapeutic strategies like beta-cell replacement or regenerative 
medicine. The existing therapies with exogenous insulin or hypoglycemic agents for type 1 
and type 2 diabetes are unsatisfactory, since they do not offer a cure and are mostly 
insufficient for preventing the secondary complications associated with diabetes [3]. 
Despite an enormous increase in our understanding of islet differentiation and 
development, there is sparse information regarding the factors and pathways that regulate 
growth, survival, and death of islet cells. The number of islet beta cells present at birth is 
mainly generated by the proliferation and differentiation of pancreatic progenitor cells, a 
process called neogenesis. Shortly after birth, beta-cell neogenesis stops and a small 
proportion of cycling beta cells can still expand the cell number  to compensate for increased 
insulin demands, albeit at a slow rate. The low capacity for self-replication in the adult is too 
limited to result in a significant regeneration following extensive tissue injury. Likewise, 
chronically increased metabolic demands can lead to beta-cell failure to compensate. 
Neogenesis from progenitor cells inside or outside islets represents a more potent 
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mechanism leading to robust expansion of the beta-cell mass, but it may require external 
stimuli. For therapeutic purposes, advantage could be taken from the surprising 
differentiation plasticity of adult pancreatic cells and possibly also from stem cells. Recently 
a large number of factors controlling the differentiation of beta-cells has  been identified. 
They are classified into the following main categories: growth factors, cytokine and 
inflammatory factors, and hormones such as PTHrP and GLP-1[4,5]. In general , treatment  
with these external stimuli can restore a functional beta-cell mass in diabetic animals, but 
further studies are required before it can be applied to humans. 
2. Parathyroid hormone-related peptide 
PTH-related peptide (PTHrP) was first discovered as the most frequent cause of the syndrome 
of humoral hypercalcemia of malignancy [6-10]. However, PTHrP mRNA is widely expressed 
under normal conditions, and gene ablation experiments have established that this peptide 
plays an essential role in normal skeletal development [11]. Human PTHrP can be produced as 
a 141-amino acid peptide or, through alternative mRNA splicing, as a protein comprising 
either 139 or 173 amino acids. PTHrP binds to the same receptor as PTH, and the biological 
responses elicited by either ligand through this common PTH1R-receptor are largely 
indistinguishable, at least with regard to mineral ion homeostasis [12-15]. For these actions of 
PTH and PTHrP, the amino-terminal (1–34) peptide fragments are sufficient, as PTH-(1–34) 
and PTHrP-(1–34) display both  high-affinity receptor binding and efficient receptor activation. 
There is a growing body of evidence, however, suggesting that the midregional and/or 
carboxy-terminal fragments of either peptide, derived through posttranslational processing 
mechanisms, also have biological activity [16-18]. However, the observed activities of 
midregional and COOH-terminal fragments of PTH and PTHrP are unlikely to be related to 
adult mineral ion homeostasis and are probably mediated through receptors that are distinct 
from the PTH1R, although these receptors have not yet been identified. 
3. Structure-activity relations in PTH and PTHRP 
PTH and PTHrP show significant sequence homology within the first 13 amino acid 
residues (Fig1), and this sequence conservation reflects the functional importance of the 
amino-terminal residues in receptor signaling [19- 21]. Between PTH and PTHrP, sequence 
homology decreases markedly in the 14–34 region, where only three amino acids are 
identical, and beyond residue 34 there is no recognizable similarity. 
For both PTH and PTHrP, the 15–34 region functions as the principal PTH1R binding 
domain, and these portions of the two peptides probably interact with overlapping regions 
of the receptor, as the two fragments compete equally for binding with radiolabeled PTH-
(1–34) or PTHrP-(1–36) to the PTH1R [22,23].These findings  also suggest that the two 
divergent receptor binding domains of PTH and PTHrP adapt similar conformations. 
The three-dimensional crystal structures of PTH or PTHrP are not known, but the peptides 
have been  analyzed extensively by nuclear magnetic resonance (NMR) spectroscopic 
methods. In general, these studies indicate that, under certain solvent conditions, PTH-(1–
34) and PTHrP-(1–36) analogs contain defined segments of secondary structure, including a 
relatively stable a-helix in the carboxy-terminal receptor-binding domain, a shorter less 
stable helix near the aminoterminal activation domain, and a flexible hinge or bend region 
connecting the two domains [24-26]. 
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Fig. 1. Parathyroid hormone (PTH) and PTH-related peptide (PTHrP) and analogs: 
functional domains and receptor selectivity determinants. A: amino acid sequences of the 
bioactive (1–34) regions of native human PTH and human PTHrP. In the schematic of 
human PTHrP, only residues that differ from human PTH are provided, and amino acids 
that are identical to the corresponding residues of PTH are represented by open circles. Bars 
represent peptide fragments that exhibit weak receptor binding (15–34) or antagonist and 
inverse agonist properties (7–34)  
Although most NMR solution studies find evidence for peptide flexibility, the question of 
whether the conformations of PTH and PTHrP recognized by the receptor are folded with 
tertiary interactions, as suggested by some studies [27-29], or extended, as suggested by 
other analyses , remains unanswered. 
4. Receptors for PTH and PTHRP 
As indicated above, PTH and PTHrP mediate their actions primarily through the PTH1R 
PTH/PTHrP receptor, a G protein-coupled receptor (GPCR) with seven membrane-
spanning helices[30]. The PTH1R forms, along with the receptors for secretin, calcitonin, 
glucagon, and several other peptide hormones, a distinct family of GPCRs that exhibit 
none of the amino acid sequence motifs found in the other subgroups of the superfamily 
of heptahelical receptors [31-32]. These peptide hormone receptors, called class II or 
family B receptors [31], can be distinguished from other GPCRs by their large,  (150 
amino acid) amino-terminal extracellular domain containing six conserved cysteine 
residues, as well as by several other conserved amino acids that are dispersed 
throughout the NH2-terminal domain, the membrane-embedded helixes, and the 
connecting loops. 
Significant progress has been made in understanding the role of the common PTH/PTHrP 
receptor, the PTH1R, in mammalian biology, particularly with regard to its normal role in 
chondrocyte growth and development, and its pathological role in two rare genetic 
disorders in humans. Amino acid residues in the PTH1R and PTH2R that are likely to be 
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important for ligand-receptor interaction and for signal transduction have been identified 
through mutagenesis methods and through photoaffinity cross-linking techniques. 
Although these studies have provided new insights into the mode of ligand-receptor 
interaction, there is still much that needs to be learned about this complex process. 
5. Pancreas development 
The pancreas originates from the foregut endoderm as ventral and dorsal buds, beginning at 
embryonic day (e) 9.5 in the mouse, and the two buds later fuse at approximately e12.5 [33]. 
The endodermal epithelium proliferates in response to various fibroblast growth factors 
(FGFs) produced by the adjacent mesenchyme [34], undergoes branching morphogenesis, 
and differentiates into ductal, exocrine, and endocrine cells. Evagination and development of 
the ventral pancreatic bud is slightly delayed compared with that of the dorsal bud, and the 
ventral bud gives rise to fewer endocrine cells than does the dorsal bud [35]. The ventral and 
dorsal buds also differ with regard to the signals they require for development.  
5.1 Dynamic changes in an organism’s ß-cell mass 
In addition to maintaining ß-cell mass under normal circumstances, as just discussed, an 
organism must also be able to alter its ß-cell mass in accordance with its requirements for 
insulin. In states of insulin resistance, such as pregnancy and obesity, ß-cell mass is known 
to increase [45]. Such ß-cell mass expansion is accomplished primarily by increasing ß-cell 
proliferation, although neogenesis may also contribute. However, when compensatory ß-cell 
mass expansion is inadequate, diabetes ensues – gestational diabetes in the case of 
pregnancy, and type II diabetes in the case of obesity. Although the majority of humans do 
not become diabetic in these circumstances, a significant portion of the population is 
predisposed to ß-cell failure, for currently unknown reasons. It is likely that factors that 
regulate ß-cell proliferation may play a role, although whether the factors that regulate ß-cell 
mass expansion are the same as those that regulate ß-cell mass maintenance is unclear.       
5.2 Regulatory factors of b-cell mass expansion and maintenance 
During pregnancy, rats exhibit a greater than 50% increase in ß-cell mass, which is 
accomplished primarily through an approximate threefold increase in ß-cell proliferation 
[46]. The chief stimuli of ß-cell proliferation during pregnancy are placental lactogens (PLs), 
although prolactin (Prl) and growth hormone (GH) also have similar effects on ß-cells and 
are also elevated during pregnancy. After delivery, ß-cell mass returns to normal levels 
within 10 days through increased ß-cell apoptosis, decreased ß-cell proliferation, and ß-cell 
atrophy.  
Diet-induced obesity results in insulin resistance and ß-cell mass expansion in humans and 
mice. The C57Bl/6 mouse strain is notoriously susceptible to these effects, exhibiting a 2.2-
fold increase in ß-cell mass and proliferation after 4 months on a high-fat diet versus a 
control diet [51]. However, these mice eventually become diabetic and lose their ß-cell mass 
due to increased ß-cell apoptosis and reduced ß-cell proliferation.  
In genetic models of obesity and insulin resistance, there is also a compensatory expansion 
of ß-cell mass. For example, db/db mice, which lack a functional leptin receptor, exhibit a 
twofold increase in ß-cell mass by 8 weeks of age [52]. This timepoint correlates with the 
onset of diabetes, which progresses from glucose intolerance that is first observed between 4 
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and 6 weeks of age. A similar rat model, the Zucker diabetic fatty (ZDF) rat (fa/fa), also has a 
homozygous mutation in the gene encoding the leptin receptor. ZDF rats exhibit increased 
ß-cell mass and increased ß-cell proliferation prior to the onset of diabetes, but increased ß-
cell apoptosis prevents them from adequately expanding their ß-cell mass after the onset of 
diabetes, despite continued high rates of ß-cell proliferation [53]. This phenotype contrasts 
with what is observed in non-diabetic Zucker fatty (ZF) rats, which possess the same 
mutation as ZDF rats and also become obese and insulin resistant but do not develop 
diabetes due to sufficient ß-cell mass expansion through increased ß-cell proliferation, 
neogenesis, and hypertrophy [53].  
Another model of insufficient ß-cell mass expansion is the insulin receptor substrate two 
null mouse [Irs2–/–; 54]. Global inactivation of Irs2 results in severe insulin resistance, both 
centrally in the brain causing obesity, and peripherally, for which ß-cell mass expansion 
should be able to compensate. However, because ß-cells require Irs2 for proper proliferation 
and function, Irs2–/–mice are unable to expand their ß-cell mass, and they develop diabetes 
by 10 weeks of age. This phenotype is not observed in Irs1–/–mice, despite the fact that these 
mice exhibit similar insulin resistance, because Irs1 is not required for ß-cell mass expansion. 
These experiments provide additional evidence that Irs2 is required for ß-cell mass 
expansion in response to insulin resistance. Furthermore, overexpression of Irs2 in ß-cells 
(Rip-Irs2) is sufficient to prevent ß-cell failure in diet-induced obesity and streptozotocin-
induced diabetic models [55].  
6. The role of PTHrP in diabetes 
PTHrP was discovered in the early 1980s as the factor responsible for humoral 
hypercalcemia of malignancy. Subsequent studies found PTHrP expression to be 
widespread in almost all tissues and organs of the body. One such tissue is the islet of 
Langerhans, in which all four endocrine cell types (α, ß, Ǆ and ǅ pancreatic polypeptide 
cells) produce PTHrP. Not only is the peptide made in islets, but receptors for PTHrP also 
seem to be present on ß cells. To begin to evaluate the possible role of PTHrP in pancreatic 
islets,  transgenic mice overexpressing PTHrP in the ß cells of islets were developed  using 
the rat insulin II promoter (RIP). These RIP-PTHrP mice displayed islet cell hyperplasia, 
significant hypoglycemia under both fasting and nonfasting conditions, as well as 
inappropriate hyperinsulinemia. Insulin expression was shown to be up-regulated both at 
the messenger RNA and protein level in whole pancreas of RIP-PTHrP mice. [58] 
PTHrP is a prohormone that is posttranslationally endoproteolytically cleaved to yield a 
family of mature secretory peptides [58-60] . These include an amino-terminal secretory 
form, which binds to and activates the recently cloned parathyroid hormone receptor [10] , 
as well as several other mid-region, and carboxyl-terminal secretory forms of the peptide. 
Since the full-length PTHrP(1-141) cDNA was used to construct the transgene, these 
experiments do not provide information regarding which of the several secretory forms is 
(or are) responsible for the hyperinsulinemia and islet hyperplasia observed. 
The phenotype does not seem to result from a developmental effect of PTHrP on the 
pancreas, because transgenic mice at 1 week of age were normoglycemic and displayed 
normal islet mass despite expression of the PTHrP transgene. In contrast, a visible increase 
in islet mass (2-fold) was observed in RIP-PTHrP mice by 12 weeks of age, and increased 
further (3- to 4-fold) by 1 yr of age. Both an increase in the number of ß cells per islet as well 
as an increase in total islet number contribute to the enhancement of islet mass in these mice. 
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The increase in islet mass in RIP-PTHrP transgenic mice does not seem to be a result of an 
increase in the proliferation rates of preexisting ß cells of the islet. Thus, the increased islet 
mass in RIP-PTHrP mice most likely results from a decrease in the normal rate of ß-cell 
turnover or apoptosis and/or enhanced neogenesis(62). In other cell types like 
chondrocytes, neuronal cells, and prostate carcinoma cells, PTHrP has been shown to have 
an antiapoptotic or protective effect against cell death. In line with this, ß cells of the RIP-
PTHrP mice have also been shown to be more resistant to the cytotoxic effects of high doses 
of the diabetogenic agent streptozotocin (STZ): RIP-PTHrP transgenic mice remain relatively 
euglycemic unlike their normal littermates, which become severely diabetic following STZ 
injection. Histologically, the resistance to the diabetogenic effects of STZ seems to result, at 
least partially, from PTHrP-induced resistance to STZ-mediated ß-cell death (63).  
Another surprising feature of the RIP-PTHrP mouse is that despite impressive 
overproduction of PTHrP, systemic hypersecretion of PTHrP does not occur and 
hypercalcemia does not develop. This is surprising because PTHrP is clearly sorted into the 
regulated secretory pathway [64-67], and is copackaged with insulin in islet cells [66], and is 
secreted in response to insulin secretagogues [66]. This may reflect clearance of PTHrP by 
the liver after it is secreted into the portal circulation. 
These findings suggest that PTHrP may have potential in  therapeutic strategies designed to 
increase ß-cell mass and function. Specifically, this peptide could prove to be valuable in 
improving islet transplant survival in type 1 diabetes. 
Recently, the discovery of a family of islet homeobox genes including 
PDX1/STF1/IPF1/IDX1, ISL1, PAX-4, PAX-6, NeuroD/ß-2 and others [74-77] and putative 
islet growth factors such as GH, PRL, placental lactogen, hepatocyte growth factor, the reg 
family of proteins, and the recently identified protein, INGAP [78-80] has focused attention 
on the mechanisms responsible for pancreatic and islet development and on the 
mechanisms whereby islet neogenesis occurs in states of islet injury, subtotal 
pancreatectomy, or pregnancy, and whereby normal islet mass is sustained throughout life. 
If PTHrP does not have an obvious role in islet cell proliferation or in apoptosis of existing 
islets but is nevertheless very potent in increasing islet mass, it is possible that PTHrP may 
play a role in normal islet neogenesis or in differentiation from uncommitted precursor cells, 
such as ductular epithelial cells. In this regard, it has been reported that PTHrP is indeed 
expressed in pancreatic ductular cells [81]. 
For attaining a well-functioning ß-cell mass, PTHrP is a very promising candidate among 
insulinotropic peptides including hepatocyte growth factor, GLP-1, and exendin-4 [82]. 
Indeed, rat insulin gene–promoted overexpression of PTHrP in mouse islets presented a 
twofold increase in total islet number and total islet mass, as well as in insulin content [83]. 
In contrast, transgenic mice expressing exendin-4, a long-acting GLP-1–like peptide, 
presented no remarkable change in total islet number and total islet mass [84]. Thus, PTHrP 
seems to be potent in upholding a well-functioning ß-cell mass.  
7. Preleminary clinical observations 
As had been the case in so many other tissues, the observation of physiological and 
pathophysiological responses to PTH was documented in the islet and in insulin target 
tissues long before the discovery of PTHrP. The significance of these observations was 
difficult to fathom at the time, since no obvious physiological link between calcium 
homeostasis and glucose metabolism readily suggested itself. For example, it had long 
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been observed that glucose intolerance and frank diabetes occurred in association with 
hyperparathyroidism more often than would be expected by random coincidence [85]. It 
also had been shown that the elevated PTH concentrations in patients with primary 
hyperparathyroidism induced both mild peripheral insulin resistance and augmented 
insulin response to hyperglycemia. In the majority of reports, the data on insulin response 
are difficult to interpret because of the effects on insulin secretion of the hypercalcemia 
that accompany the elevated circulating PTH concentrations in patients with 
hyperparathyroidism. In one study, however, normal volunteers made hypercalcemic by 
PTH injection over 8 days demonstrated augmented insulin responses to glucose and to 
intravenous tolbutamide, while a control group rendered similarly hypercalcemic by 
calcium infusion failed to demonstrate an augmented insulin response to glucose [86]. To 
investigate the direct effects of PTH on pancreatic islets in vitro, Fadda et al. [87], before 
the description of PTHrP as an islet peptide,examined insulin secreation from isolated 
pancreatic islets in response to PTH-(1-34) and PTH- (l-84). These studies showed that 
PTH augmented both the first and second phases of secretion in response to 16.7 mM 
glucose. 
The suggested link between parathyroid gland function and the pancreatic islet was met, 
quite appropriately, with skepticism and for two reasons. First, as noted above, it was very 
difficult to envision a physiological scenario in which PTH could be construed as 
participating in normal islet regulation. Second, studies such as that reported by Fadda et al. 
[87] generally required concentrations of PTH far in excess of those encountered in 
hyperparathyroidism to observe an effect. One was therefore forced to conclude either that 
these effects were nonphysiological and therefore meaningless or to postulate that there is 
another natural peptide of physiological import within the islet that might be mediating 
these effects in the islet. At the time these studies were performed, no such normal islet 
product was known. As is now obvious, islet derived PTHrP is a candidate worthy of 
consideration. 
In 1992,Ishida et al,[88] reported that type 2 diabetics presented higher serum PTHrP 
levels than control subjects. However, in that study  no stimulation tests were done to 
demonstrate whether PTHrP is released from the pancreas in response to insulin 
secretagogues like glucose or calcium. Extensive studies have demonstrated that an 
increase in the cytosolic calcium is essential for glucose-stimulated insulin release[89]. 
Indeed, one of the mature, secretory forms of PTHrP, called mid-region PTHrP,was 
demonstrated by Wu et. al. [90] to increase cytosolic calcium levels in a pancreatic b cell 
line. Increased cytosolic calcium levels have also been reported in insulinoma cells, 
supporting the notion that PTHrP is not only secreted by pancreatic cells, but might also 
play an autocrine or paracrine role within the islets themselves[91].In 2006,Shor et al [92] 
examined the effects of two stimulatory secretagogues -glucose and calcium-after  an oral 
glucose load (75gr) to healthy controls. They reported that PTHrP and insulin rose in 
parallel although this response was not observed during the calcium load. Moreover , 
they found significant differences in basal serum PTHrP levels particularly in type 2 
versus type 1 diabetics and healthy controls. Ishida et al[88], proposed that elevated 
PTHrP levels might play a compensatory role in calcium homeostasis in diabetic patients. 
They speculate that these patients often exhibit osteopenia and lower than normal PTH 
levels with a net result the preservation of normal serum calcium levels. 
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Performing PTHrP serum determinations in a fasting state in type 2 diabetics by our group 
[93] we have found that PTHrP  was  statistically significant correlated with glucose in type 
2 diabetes (r:0,992-p<0,0001)  and in normal subjects in the fasting state (r:0,908-p<0,0001). 
Additionally, PTHrP serum levels exhibited a significant increase in type 2 diabetes 
compared to control subjects (Diabetics-PTHrP(Median):380 pg/ml versus Normals-
PTHrP(Median):180 pg/ml , p<0,001). Interestingly, PTHrP showed a positive correlation 
with insulin levels only among healthy individuals presumably due to defective glucose 
stimulated insulin secretion known to occur in type 2 diabetics. 
In  conclusion ,the recognition  that PTHrP-a protein mostly indentified as a tumor product 
in cases of humoral malignant hypercalcemia, is found in almost every body tissue 
including the pancreas , where it is processed into multiple secreatory forms,co-packed with 
insulin , and secreted in a regulatory fashion in response to insulin secretagogeus , opens 
new directions in the autocrine/paracrine role of PTHrP in the islets of Langerhans and 
raises several questions for further experimentation in both type 1 and type 2 diabetes. 
8. References 
[1] Chang-Chen KJ.; Mullur R.; Bernal-Mizrachi E :Beta-cell failure as a complication of 
diabetes.  Rev Endocr Metab Disord .,2008, 9, 329-343. 
[2] Retnakaran R.;Qi Y.; Sermer M.; Connelly PW.; Hanley AJ.; Zinman B : Glucose 
intolerance in pregnancy anf future risk of pre-diabetes or diabetes. Diabetes Care., 
2008, 31, 2026-2031. 
[3] Nathan, D.M :Long-term complications of Diabetes Mellitus. N Engl J Med., 1993,328, 
1676–1685. 
[4] Legakis I.;Tsioras C.; Phenekos C : Decreased glucagon-like peptide 1 fasting levels in 
type 2 diabetes .Diabetes Care .,2003,  26, 252. 
[5] Legakis I.;Mantouridis T.;Mountokalakis T : Positive correlation of galanin with glucose 
in type 2 diabetes . Diabetes Care., 2005, 28, 759-760. 
[6] Mangin, M. A. C.; Webb. B. E.; Dreyer, J. T.; Posillico, K.; Ikeda, E. C.;Weir, A. F.; Stewart, 
N. H.; Bander, L. ;Milstone, D. E.; Barton, U. ;Francke, Broadus, A.E: Identification 
of a cDNA encoding a parathyroid hormone-like peptide from a human tumor 
associated with humoral hypercalcemia of malignancy. Proc. Natl. Acad. Sci. USA., 
1988, 85, 597–601. 
[7] Moseley, J. M.; M. Kubota, H.; Diefenbach-Jagger, R. E. H.;Wettenhall, B. E. Kemp.; L. J. 
Suva.; C. P. Rodda.; P. R. Ebeling.; P. J. Hudson.; J. D. Zajac  and J. T. Martin : 
Parathyroid hormone-related protein purified from a human lung cancer cell line. 
Proc. Natl. Acad. Sci. USA,1987,  84, 5048–5052. 
[8] Stewart, A. F. R.; Horst, L. J. ;Deftos, E. C. ;Cadman, R. Lang.;  Broadus,A.E: Biochemical 
evaluation of patients with cancer-associated hypercalcemia. Evidence for humoral 
and non-humoral groups. N. Engl. J. Med., 1980, 303, 1377–1381. 
[9] Strewler, G. J.; Stern, P.H.; Jacobs, J.W.; Eveloff,J.; Klein, R.F.;Leung, S.C.; Rosenblatt, 
M.;Nissenson, R.A: Parathyroid hormone-like protein from human renal carcinoma 
cells. Structural and functional homology with parathyroid hormone. J. Clin. 
Invest., 1987, 80, 1803–1807. 
[10] Suva, L. J.;Winslow, G. A.; Wettenhall, R. E. ;Hammonds, R. G. ;Moseley, J. M.; 
Diefenbach-Jagger, H.; Rodda, C. P.; Kemp, B. E. ; Rodriguez, H.; Chen, E. Y. 
;Hudson, P. J. ; Martin, J. T.;Wood, W. I :A parathyroid hormone-related protein 
www.intechopen.com
The Role of Parathyroid Hormone–Related  
Protein (PTHRP) in the Pathophysiology of Diabetes Mellitus  
 
47 
implicated in malignant hypercalcemia: cloning and expression. Science., 1987,237, 
893–896. 
[11] Karaplis, A. C.;Luz,A.; Glowacki, J.;Bronson,R.; Tybulewicz,V.; Kronenberg, H. M. ;R. 
C. Mulligan, R. C.: Lethal skeletal dysplasia from targeted disruption of the 
parathyroid hormone-related peptide gene. Genes Dev.,1994, 8, 277–289. 
[12] Everhart-Caye, M.;  Inzucchi, S.E.; Guinness-Henry, J.; Mitnick,M.A.; Stewart, A.F.: 
Parathyroid hormone (PTH)-related protein(1–36) is equipotent to PTH-(1–34) in 
humans. J. Clin. Endocrinol. Metab., 1996, 81, 199–208. 
[13] Fraher, L. J.; Hodsman, A. B.;Jonas,K.; D. Saunders,D.; Rose,C.I.; Henderson, J.E.; 
Hendy, G.N.;  Goltzman, D: A comparison of the in vivo biochemical responses to 
exogenous parathyroid hormone-(1–34) [PTH-(1–34)] and PTH-related peptide-(1–
34) in man. J. Clin. Endocrinol. Metab., 1992, 75, 417–423. 
[14] Horiuchi, N.;Caulfield, M.P.;Fisher, J.E.;Goldman, M.E.; McKee, R.L.; Reagan, J.E.; 
Levy, J.J;Nutt, R.F.; Rodan, S.B.; Schofield, T.L.; Clemens, T.L.; Rosenblatt, M : 
Similarity of synthetic peptide from human tumour to parathyroid hormone in 
vivo and in vitro. Science., 1987, 238, 1566–1568. 
[15] Kemp, B. E.; Mosely, J.M.; Rodda, C.P.; Ebeling, P.R.; R. E. Wettenhall, H.; Stapleton, 
D.; Diefenbach-Jagger, H.; Ure, F.; Michelangali, V.P.; Simmons, H.A.; Raisz, L.G.; 
Martin, T.J: Parathyroid hormone-related protein of malignancy: active synthetic 
fragments. Science., 1987, 238, 1568–1570. 
[16] Kovacs, C. S.; Lanske, B.; Hunzelman, J.L.; Guo, J.; Karaplis, A.C.; Kronenberg, H.M: 
Parathyroid hormonerelated peptide (PTHrP) regulates fetal placental calcium 
transport through a receptor distinct from the PTH/PTHrP receptor. Proc. Natl. 
Acad. Sci. USA., 1996, 93, 15233–15238. 
[17] Potts, J. T. Jr.; Juppner, H. Parathyroid hormone and parathyroid hormone-related 
peptide in calcium homeostasis, bone metabolism, and bone development: the 
proteins, their genes, and receptors. In: Metabolic Bone Disease, edited by L. V. 
Avioli, L.V.; Krane, S.M. New York: Academic, 1997; pp. 51–94. 
[18] Wu, T. L.; Vasavada, R.C.;Yang, K.; Massfelder, T.; Ganz, M.; Abbas, S.K.; Care, A.D.; 
Stewart, A.F: Structural and physiological characterization of the mid-region 
secretory species of parathyroid hormone-related protein. J. Biol. Chem., 1996, 271, 
24371–24381. 
[19] Goltzman, D.; Peytremann, A; Callahan, E.; Tregear, G.W.; Potts, Jr :Analysis of the 
requirements for parathyroid hormone action in renal membranes with the use of 
inhibiting analogues. J. Biol. Chem., 1975, 250, 3199–3203. 
[20] Horiuchi, N.; Holick, M.F.; Potts, J.T.;Jr., Rosenblatt, M:A parathyroid hormone 
inhibitor in vivo: design and biologic evaluation of a hormone analog. Science., 
1983, 220, 1053– 1055. 
[21] Tregear, G. W.; Rietschoten, J.Van.; Greene, E.; Keutmann, H.T.; Niall, H.D.; Reit, B.; 
Parsons, J.A.; Potts, Jr : Bovine parathyroid hormone: minimum chain length of 
synthetic peptide required for biological activity. Endocrinology.,1973, 93, 1349–
1353. 
[22] Abou-Samra, A.-B.; Uneno, S.; Ju¨ppner, H.; Keutmann, H.; Potts, J.T.; Segre, 
G.V.;Nussbaum, S.R: Nonhomologous sequences of parathyroid hormone and the 
parathyroid hormone related peptide bind to a common receptor on ROS 17/2.8 
cells. Endocrinology., 1989, 125, 2215–2217. 
www.intechopen.com
  
Medical Complications of Type 2 Diabetes 
 
48
[23] Caulfield, M. P.; Rosenblatt. M.:Parathyroid hormone receptor interactions. Trends 
Endocrinol. Metab., 1990, 2, 164–168. 
[24] Barden, J.; Cuthbertson, R.; Jia-Zhen, W.; Moseley, J.; Kemp,B.: Solution structure of 
parathyroid hormone related protein (residues 1–34) containing an Ala substituted 
for an Ile in position 15 (PTHrP[Ala15]-(1–34)). J. Biol. Chem., 1997, 273, 29572– 
29578. 
[25] Marx, U.; Austermann, S.; Bayer, P.; Adermann, K.; Ejchart, A.; Sticht, H.; Walters, S.; 
Schmid, F.; Jaenicke, R.;Forssmann, W.; Rosch,P.: Structure of human parathyroid 
hormone 1–37 in solution. J. Biol. Chem., 1995, 270, 15194–15202. 
[26] Pellegrini, M.; Royo, M.;Rosenblatt, M.; Chorev, M.; Mierke,D.: Addressing the tertiary 
structure of human parathyroid hormone-(1–34). J. Biol. Chem., 1998, 273, 10420–
10427. 
[27] Barden, J. A.; Kemp, B.E.: Stabilized NMR structure of the hypercalcemia of 
malignancy peptide PTHrP[Ala-26](1– 34)amide. Biochim. Biophys. Acta ., 1994, 
1208, 256–262. 
[28] Cohen, F. E.; Strewler, G.J.; Bradley, M.S.;Carlquist, M.; Nilsson, M.; Ericsson, M.; 
Ciardelli, T.L.;and R. A. Nissenson, R. A.: Analogues of parathyroid hormone 
modified at positions 3 and 6: effects on receptor binding and activation of adenylyl 
cyclase in kidney and bone. J. Biol. Chem., 1991, 266, 1997–2004. 
[29] Gardella, T. J., M. D. Luck, A. K. Wilson, H. T. Keutmann, S. R. Nussbaum, J. T. Potts, 
Jr., and H. M. Kronenberg. Parathyroid hormone (PTH)/PTH-related peptide 
hybrid peptides reveal functional interactions between the 1–14 and 15–34 domains 
of the ligand. J. Biol. Chem.; 1995,  270: 6584–6588. 
[30] Mannstadt M, Juppner H, Gardella J T: Receptors for PTH and PTHrP: their biological 
importance and functional properties. Am. J. Physiol.;  1999, 277, 665-675 
[31] Ji, T. H.; Grossmann, M.; Ji,I.: G protein-coupled receptors. I. Diversity of receptor-
ligand interactions. J. Biol. Chem., 1998,  273, 17299–17302. 
[32] Segre, G. V.;  Goldring,S.R.: Receptors for secretin, calcitonin, parathyroid hormone 
(PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagon-like peptide 1, 
growth hormone-releasing hormone, and glucagon belong to a newly discovered G 
protein-linked receptor family. Trends Endocrinol. Metab.,1993, 4: 309–314. 
[33] Ackerman AM.; Gannon M :Molecular regulation of pancreatic b-cell mass 
development ,maintenance and expansion . Journal of Molecular Endocrinology., 
2007, 38, 193-206. 
[34] Bhushan, A.; Itoh, N.; Kato, S.; Thiery, J.P.; Czernichow, P.; Bellusci, S.; Scharfmann, R.: 
Fgf10 is essential for maintaining the proliferative capacity of epithelial progenitor 
cells during early pancreatic organogenesis. Development ., 2001, 128 , 5109–5117. 
[35] Spooner, B.S.; Walther, B.T.; Rutter,W.J.: The development of the dorsal and ventral 
mammalian pancreas in vivo and in vitro. Journal of Cell Biology., 1970, 47 , 235–
246. 
[36] Harrison, K.A.; Thaler, J.; Pfaff, S.L.; Gu, H.; Kehrl, J.H.: Pancreas dorsal lobe agenesis 
and abnormal islets of Langerhans in Hlxb9-deficient mice. Nature Genetics., 1999, 
23, 71–75. 
[37] Li, H.; Arber, S.; Jessell, T.M.; Edlund, H.: 1999 Selective agenesis of the dorsal 
pancreas in mice lacking homeobox gene Hlxb9. Nature Genetics., 1999, 23, 67–70. 
www.intechopen.com
The Role of Parathyroid Hormone–Related  
Protein (PTHRP) in the Pathophysiology of Diabetes Mellitus  
 
49 
[38] Ahlgren, U.; Pfaff, SL.; Jessell, T.M.; Edlund ,T.; Edlund, H.: Independent requirement 
for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature., 1997, 385, 
257–260. 
[39] Guz,Y.; Montminy, M.; Stein, R.; Leonard, J.; Gamer, L.; Wright, C.; Teitelman, G.: 
Expression of murine STF-1, a putative insulin gene transcription factor, in beta 
cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine 
progenitors during ontogeny. Development., 1995, 121, 11–18. 
[40] Melloul D.; Marshak S .; Cerasi E : Regulation of pdx-1 gene expression. Diabetes., 2002, 
51 , 320–325. 
[41] Offield, M.F.; Jetton, T.L.; Labosky, P.A.; Ray, M.; Stein, R.W.; Magnuson, M.A.; 
Hogan, B.L.; Wright, C.V: PDX-1 is required for pancreatic outgrowth and 
differentiation of the rostral duodenum. Development., 1996, 122, 983–995. 
[42] Stoffers, D.A.; Zinkin, N.T.; Stanojevic, V.; Clarke, W.L.; Habener,J.F: Pancreatic 
agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding 
sequence. Nature Genetics., 1997b, 15, 106–110. 
[43] Krapp, A.; Knofler, M.; Ledermann, B.; Burki, K.; Berney, C.; Zoerkler, N.; 
Hagenbuchle, O.;  Wellauer, P.K.: 1998 The bHLH protein PTF1-p48 is essential for 
the formation of the exocrine and the correct spatial organization of the endocrine 
pancreas. Genes and Developmen., 1998, 12 , 3752–3763. 
[44] Kawaguchi, Y.; Cooper, B.; Gannon, M.; Ray, M.; MacDonald, R.J.; Wright, C.V.: The 
role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic 
progenitors. Nature Genetics., 2002, 32, 128–134. 
[45] Rhodes, C.J: 2005 Type 2 diabetes – a matter of beta-cell life and death? Science., 2005, 
307, 380–384. 
[46] [46] Scaglia, L.; Smith, F.; Bonner-Weir, S.: Apoptosis contributes to the involution of 
beta cell mass in the post partum rat pancreas. Endocrinology., 1995, 136 , 5461–
5468. 
[47] Vasavada, R.C.; Garcia-Ocaña, A.; Zawalich, W.S.; Sorenson, R.L.; Dann, P.; Syed, M.; 
Ogren, L.; Talamantes, F.; Stewart, A.F.: Targeted expression of placental lactogen 
in the beta cells of transgenic mice results in beta cell proliferation, islet mass 
augmentation, and hypoglycemia. Journal of Biological Chemistry., 2000, 275, 
15399–15406. 
[48] Cozar-Castellano, I.; Weinstock, M.; Haught, M.; Velazquez-Garcia, S.; Sipula, D.; 
Stewart, A.F.: Evaluation of beta-cell replication in mice transgenic for hepatocyte 
growth factor and placental lactogen: comprehensive characterization of the G1/S 
regulatory proteins reveals unique involvement of p21cip. Diabetes., 2006a, 55, 70–
77. 
[49] Garcia-Ocaña, A.; Takane, K.K.; Syed, M.A.; Philbrick, W.M.; Vasavada, R.C.; Stewart, 
A.F.: Hepatocyte growth factor overexpression in the islet of transgenic mice 
increases beta cell proliferation, enhances islet mass, and induces mild 
hypoglycemia. Journal of Biological Chemistry., 2000, 275 , 1226–1232. 
[50] Garcia-Ocaña, A.; Vasavada, R.C.; Cebrian, A.; Reddy, V.; Takane, K.K.; Lopez-
Talavera,J-C.; Stewart, A.F.: Transgenic overexpression of hepatocyte growth factor 
in the beta-cell markedly improves islet function and islet transplant outcomes in 
mice. Diabetes., 2001, 50 , 2752–2762. 
www.intechopen.com
  
Medical Complications of Type 2 Diabetes 
 
50
[51] Sone, H.; Kagawa, Y.: Pancreatic beta cell senescence contributes to the pathogenesis of 
type 2 diabetes in high-fat diet-induced diabetic mice. Diabetologia., 2005, 48 , 58–
67. 
[52] Wang, Q.; Brubaker, P.L.: Glucagon-like peptide-1 treatment delays the onset of 
diabetes in 8 week-old db/db mice. Diabetologia., 2002, 45 , 1263–1273. 
[53] Pick, A.; Clark, J.; Kubstrup, C,.; Levisetti, M.; Pugh, W.; Bonner-Weir, S.; Polonsky, K 
.:1998 Role of apoptosis in failure of beta-cell mass compensation for insulin 
resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes., 1998, 
47, 358–364. 
[54] Kubota, N.; Terauchi, Y.; Tobe, K.; Yano, W.; Suzuki, R.; Ueki, K.; Takamoto, I.; Satoh, 
H.; Maki, T.; Kubota, T: Insulin receptor substrate 2 plays a crucial role in beta cells 
and the hypothalamus. Journal of Clinical Investigation., 2004, 114 , 917–927. 
[55] Hennige, A.M.; Burks, D.J.; Ozcan,U.; Kulkarni, R.N.; Ye, J.;Park, S.; Schubert, M.; 
Fisher, T.L.; Dow, M.A.; Leshan, R: Upregulation of insulin receptor substrate-2 in 
pancreatic beta cells prevents diabetes. Journal of Clinical Investigation., 2003, 112 , 
1521–1532. 
[56] Kitamura, T.; Nakae, J.; Kitamura, Y.; Kido, Y.;Biggs, W.H III.;Wright, C.V.E.; 
White,M.F.; Arden, K.C.; Accili, D: The forkhead transcription factor Foxo1 links 
insulin signaling to Pdx1 regulation of pancreatic beta cell growth. Journal of 
Clinical Investigation., 2002, 110, 1839–1847. 
[57] Okamoto, H.; Hribal, M.L.; Lin, H.V.; Bennett, W.R.; Ward, A.; Accili, D: Role of the 
forkhead protein FoxO1 in beta cell compensation to insulin resistance. Journal of 
Clinical Investigation., 2006, 116 , 775–782. 
[58] García-Ocaña A.; Vasavada CA .; Takane KK.; , Cebrian A .;Lopez-Talavera CJ ..; 
Stewart AF : Using ß-Cell Growth Factors to Enhance Human Pancreatic Islet 
Transplantation. Journ Endocr. Metab.,2001,86, 984-988. 
[59] Broadus, A. E.; Stewart, A. F.  in The Parathyroids: Basic and Clinical Concepts (Bilezikian, 
J. P., Levine, M. A., and Marcus, R., eds), Raven Press, New York, 1994; pp. 259-294. 
[60] Orloff, J. J.; Reddy, D.; dePapp, A. E.; Yang, K. H.;Soifer, N. S.; Stewart, A. F.  
Endocrine Rev., 1994, 15, 40-60 . 
[61] Jüppner, H.; Abou-Samra, A.-B.; Freeman, M.; Kong, X. F.; Schipani, E.; Richards, J.; 
Kolakowski, L. F.; Jr., Hock, J.; Potts, J. T.; Jr., Kronenberg, H.; Segre, G. V.  Science., 
1991, 254, 1024-1026.  
[62] Porter, S.E.; Sorenson, R.L.; Dann, P.; García-Ocaña, A.; Stewart, A.F.; Vasavada,R.C.: 
1998 Progressive pancreatic islet hyperplasia in the islet-targeted, PTH-related 
protein-overexpressing mouse.  Endocrinology., 1998, 139, 3743–3751.  
[63] Vasavada, R.C.; Cebrian, A.; García-Ocaña, A.:  PTH-related protein (PTHrP): in vivo 
inhibition of streptozotocin-induced ß cell death in transgenic mice. Proceedings of 
the 82nd Annual Meeting of The Endocrine Society , Canada, 2000, p. 76.  
[64] Philbrick, W.M.; Wysolmerski, J.J.; Galbraith, S.; Holt, E.; Orloff, J.J.; Yang, K.H.; 
Vasavada, R.C.;Weir, E.C.; Broadus, A.E.; Stewart, A.F.: 1996 Defining the 
physiologic roles of parathyroid hormone-related protein in normal physiology. 
Physiol Rev., 1996, 76, 127–173. 
[65] Wysolmerski, J.J.; Stewart, A.F: The physiology of parathyroid hormone-related 
protein: an emerging role as a developmental factor. Ann Rev Physiol., 1998, 60, 
431–460. 
www.intechopen.com
The Role of Parathyroid Hormone–Related  
Protein (PTHRP) in the Pathophysiology of Diabetes Mellitus  
 
51 
[66] Plawner, L.L.; Philbrick, W.M.; Burtis, W.J.; Broadus, A.E.; Stewart, A.F.: 1995 Secretion 
of parathyroid hormone-related protein: cell-specific secretion via the regulated vs. 
the constitutive secretory pathway. J Biol Chem., 1995, 270, 14078–14084. 
[67] Deftos, L.J.; Burton, D.W.; Brandt, D.W:  PTH-like protein is a secretory product of 
atrial myocytes. J Clin Invest., 1993, 92, 727–735. 
[68] Ju¨ppner, H.; Abou-Samra, A-B.; Freeman, M.; Kong, X.F.; Schipani, E.; Richards, J.; 
Kolakowski, L.F. Jr.; Hock, J.; Potts, J.T. Jr.; Kronenberg, H.M.; Segre, G.V: A G 
protein-linked receptor for parathyroid hormone and parathyroid hormone-related 
peptide. Science., 1991, 254, 1024–1026. 
[69] Abou-Samra, A-B.; Ju¨ppner, H.; Force, T.; Freeman, M.W.; Kong, X-F.; Schipani, E.; 
Urena, P.; Richards, J.; Bonventre, J.V.; Potts, J.T .Jr.; Kronenberg, H.M.; Segre, G.V: 
Expression cloning of a common receptor for parathyroid hormone and 
parathyroid hormone-related peptide from rat osteoblast-like cells: a single 
receptor stimulates intracellular accumulation of both cAMP and inositol 
triphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A., 
1992, 89, 2732–2736. 
[70] Stork, P.J.S.; Schmitt, J.M: Crosstalk between cAMP and MAP kinase signaling in the 
regulation of cell proliferation. Trends Cell Biol ., 2002, 12, 258–266. 
[71] Burgering, B.M.T.; Bos, J.L: Regulation of Ras-mediated signalling: more than one way 
to skin a cat. Trends Biochem Sci., 1995, 20, 18–22. 
[72] Vossler, M.R.; Yao, H.; York, R.D.; Pan, M-G.; Rim, C.S.; Stork, P.J.S: cAMP activates 
MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell ., 1997, 
89, 73–82. 
[73] Chen, T.; Cho, R.W.; Stork, P.J.S.; Weber, M.J: Elevation of cyclic adenosine 3’,5’-
monophosphate potentiates activation of mitogen-activated protein kinase by 
growth factors in LNCaP prostate cancer cells. Cancer Res., 1991, 59, 213–218. 
[74] Miller, C.P.; McGehee, R.E.; Habener, J.F: IDX-1: a new homeodomain transcription 
factor expressed in rat pancreatic islets and duodenum that transactivates the 
somatostatin gene. EMBO J., 1994, 13, 1145–1156. 
[75] Leonard, J.; Peers, B.; Johnson, T.; Ferreri, K.; Lee, S.; Montminy, M.:  Characterization 
of somatostatin transactivating factor-1, a novel homeobox factor that stimulates 
somatostatin expression in pancreatic islet cells. Mol Endocrinol., 1993, 7, 1275–
1283. 
[76] Jonsson, J.; Carlsson, L.; Edlund,T.; Edlund, H: Insulin promoter factor-1 is required for 
pancreas development in mice. Nature., 1994, 371, 606–609. 
[77] Ahlgren, U.; Pfaff, S.; Jessell, T.M.; Edlund, T.; Edlund, H.: 1997 Independent 
requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. 
Nature., 1997, 385, 257–260. 
[78] Finegood, D.T.; Scaglia, L.; Bonner-Weir, S.: Perspectives in diabetes dynamics of ß-cell 
mass in the growing rat pancreas. Estimation with a simple mathematical model. 
Diabetes., 1995, 44, 249–256. 
[79] Otonkoski, T.; Cirulli, V.; Beattie, G.M.; Mally, M.I.; Soto, G.; Rubin, J.S.; Hayek, A: A 
role for hepatocyte growth factor/scatter factor in fetal mesenchyme-induced 
pancreatic ß-cell growth. Endocrinology., 1996, 137, 3131–3139. 
[80] Rafaeloff, R.; Pittenger, G.L.; Barlow, S.W.; Qin, X.F.; Yan ,B.; Rosenberg. L.; Duguid, 
W.P.; Vinik, A.I.: Cloning and expression of the pancreatic islet neogenesis-
www.intechopen.com
  
Medical Complications of Type 2 Diabetes 
 
52
associated protein (INGAP) gene and its expression in islet neogenesis in hamsters. 
J Clin Invest., 1997, 99, 2100–2109. 
[81] Gaich, G.; Orloff, J.J.; Atillasoy, E.J.; Burtis, W.J.; Ganz, M.B.; Stewart, A.F: Amino-
terminal parathyroid hormone-related protein: specific binding and cytosolic 
calcium responses in at insulinoma cells. Endocrinology., 1992, 132, 1402–1409. 
[82] Drucker, DJ:  Glucagon-like peptides: regulators of cell proliferation, differentiation, 
and apoptosis. Mol Endocrinol., 2003, 7 , 161 –171, 
[83] Vasavada, R.C.; Cavaliere, C.; D’Ercole, A.J.; Dann, P.; Burtis, W.J.; Madlener, A.L.; 
Zawalich, K.; Zawalich, W.; Philbrick, W.; Stewart, A.F.: Overexpression of 
parathyroid hormone-related protein in the pancreatic islets of transgenic mice 
causes islet hyperplasia, hyperinsulinemia, and hypoglycemia. J Biol Chem ., 1996, 
271 ,1200 –1208. 
[84] Baggio, L.; Adatia, F.; Bock, T.; Brubaker, P.L.; Drucker, D.J.: Sustained expression of 
exendin-4 does not perturb glucose homeostasis, ß-cell mass, or food intake in 
metallothionein-preproexendin transgenic mice. J Biol Chem., 2000, 275 , 34471 –
34477.  
[85] Ijunghall, S.; M. Palmer, G.; Akerstrom,  Wide, L: Diabetes mellitus, glucose tolerance 
and insulin response to glucose in patients with primary hyperparathyroidism 
before and after parathyroidectomy. Eur. J. Clin. Invest., 1983, 13, 373-377. 
[86] Kim, H.; R. K. Kalkhoff, N. V. ; Costrini, J. M.; Cerletty.; Jacobson,M.: Plasma insulin 
disturbances in primary hyperparathyroidism. J. Clin. Invest., 1971, 50, 2596-2605. 
[87] Fadda, G. Z.; M. Ak&ial, L. G.;Lipson.; Massry, S.G.: Direct effect of parathyroid 
hormone on insulin secretion from pancreatic islets. Am. J. Physiol., 1990, 258 
(Endocrinol Metab. 21), E975-E984. 
[88] Ishida, H.; Suzuki, K.; Someya, Y.:Possible compensatory role of parathyroid hormone 
–related peptide on maintenance of calcium homeostasis in patients with non-
insulin –dependant diabetes mellitus. Acta Endocrinologica., 1993,129, 519-524. 
[89] De Marinis, L.; Merlini, G. ;  Makhoul, O.; Barbarino, A.: Calcium antagonists and 
hormone release :IV.Role of calcium in glucose-stimulated early phase insulin in 
vivo. J Endocrinol Invest., 1982 ,5, 121-4. 
[90] Wu, T.L.; Vasavada,  R.C.; Yang, K.; Massfclder, T.; Ganz, M.; Abbas, S.K .: Structural 
and physiologic characterization of the mid-region secretory species of parathyroid 
hormone –related protein. J Biol Chem., 1996, 271, 24371-24381. 
[91] Drucker, D.J .;Asa, S.L.; Henderson, J.; Glotzman, D.: The PTHrP gene is expressed in 
the normal and neoplastic human endocrine pancreas . Mol Endocrinol ., 1989, 
1589-1595. 
[92] Shor, R.; Halabe, A.; Aberbuh, E.;Matas, Z.;Fux, A.;Boaz, M.;Wainstein, J.: PTHrP and 
insulin levels following oral glucose and calcium administration. European Journal 
of Internal Medicine., 2006, 17, 408-411. 
[93] Legakis, I.;Mantouridis, T.: Positive correlation of PTH-related peptide with glucose in 
type 2 diabetes. Exp Diabetes Res., 2009,31. 
www.intechopen.com
Medical Complications of Type 2 Diabetes
Edited by Dr. Colleen Croniger
ISBN 978-953-307-363-7
Hard cover, 412 pages
Publisher InTech
Published online 12, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Obesity and type 2 diabetes are increasing worldwide problems. In this book we reviewed insulin secretion in
both healthy individuals and in patients with type 2 diabetes. Because of the risk associated with progression
from insulin resistance to diabetes and cardiovascular complications increases along a continuum, we included
several chapters on the damage of endothelial cells in type 2 diabetes and genetic influences on endothelial
cell dysfunction. Cardiovascular complications occur at a much lower glucose levels, thus a review on the oral
glucose tolerance test compared to other methods was included. The medical conditions associated with type
2 diabetes such as pancreatic cancer, sarcopenia and sleep disordered breathing with diabetes were also
discussed. The book concludes with several chapters on the treatments for this disease offering us hope in
prevention and successful alleviation of the co-morbidities associated with obesity and type 2 diabetes.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ioannis Legakis (2011). The Role of Parathyroid Hormone-Related Protein (PTHRP) in the Pathophysiology of
Diabetes Mellitus, Medical Complications of Type 2 Diabetes, Dr. Colleen Croniger (Ed.), ISBN: 978-953-307-
363-7, InTech, Available from: http://www.intechopen.com/books/medical-complications-of-type-2-
diabetes/the-role-of-parathyroid-hormone-related-protein-pthrp-in-the-pathophysiology-of-diabetes-mellitus
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
